Target type: biologicalprocess
Any process that decreases the frequency, rate, or extent of the self-propelled movement of a cell or organism from one location to another in a behavioral context; the aspect of locomotory behavior having to do with movement. [GOC:dph, GOC:kmv, GOC:tb]
Negative regulation of locomotion is a fundamental biological process that governs the control and modulation of movement, ensuring appropriate responses to environmental cues and internal states. This process involves a complex interplay of neural circuits, signaling pathways, and molecular mechanisms.
Locomotion, or movement, is a complex behavior that requires the coordinated activity of numerous muscles, joints, and sensory systems. It is essential for survival, allowing organisms to search for food, avoid predators, and interact with their environment. However, uncontrolled or inappropriate movement can be detrimental. Therefore, negative regulation of locomotion is crucial for maintaining homeostasis and optimizing behavioral responses.
**Neural Circuits Involved:**
The nervous system plays a central role in regulating locomotion. Specific brain regions, such as the motor cortex, basal ganglia, and brainstem, are involved in planning, initiating, and executing movement. These regions receive sensory input from the body and integrate this information to generate motor commands.
**Signaling Pathways:**
A variety of signaling pathways, including those involving neurotransmitters, neuromodulators, and hormones, are involved in regulating locomotion. For example, dopamine, serotonin, and acetylcholine are neurotransmitters that play important roles in motor control.
**Molecular Mechanisms:**
At the molecular level, negative regulation of locomotion involves the modulation of gene expression, protein synthesis, and signaling pathways. This can involve changes in the activity of specific enzymes, receptors, and ion channels.
**Examples of Negative Regulation of Locomotion:**
- **Stopping:** When an organism encounters an obstacle or a threat, it must stop moving to avoid danger or injury. This requires the activation of inhibitory neurons that suppress the activity of motor neurons, leading to muscle relaxation and cessation of movement.
- **Slowing down:** In certain situations, organisms may need to slow down their movement, such as when navigating a complex environment or conserving energy. This involves reducing the frequency and intensity of muscle contractions.
- **Changing direction:** To navigate effectively, organisms must be able to change direction. This involves coordinating the activity of different muscle groups to alter the body's orientation.
- **Fine-tuning movement:** Negative regulation is also essential for fine-tuning movement, ensuring smooth and precise motor control. This involves making small adjustments to muscle activity based on sensory feedback.
**Consequences of Dysregulation:**
Dysregulation of negative regulation of locomotion can lead to a variety of movement disorders, such as Parkinson's disease, Huntington's disease, and cerebellar ataxia. These conditions are characterized by uncontrolled movements, tremors, and difficulty coordinating movement.
In conclusion, negative regulation of locomotion is an essential biological process that ensures appropriate and controlled movement, facilitating effective interactions with the environment and promoting survival. This complex process involves a vast network of neural circuits, signaling pathways, and molecular mechanisms, highlighting the intricate nature of motor control.'
"
Protein | Definition | Taxonomy |
---|---|---|
Growth hormone secretagogue receptor type 1 | A growth hormone secretagogue receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q92847] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
substance p | peptide | neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent | |
l 692429 | L 692429: stimulates release of growth hormone; RN refers to (R)-isomer; structure given in first source | ||
l 163191 | |||
cp 424391 | CP 424391: a growth hormone secretagogue; structure in first source | ||
hexarelin | hexarelin: a synthetic growth hormone releasing peptide; structurally similar to GHRP-6, with the substitution of D-Trp with its 2-methyl derivative; more potent & stable and less toxic than GHRP-6 | ||
sm 130686 | SM 130686: a growth hormone secretagogue; structure in first source | ||
macimorelin | |||
tabimorelin | tabimorelin: a growth hormone secretagogue; structure in first source | ||
l 162752 | |||
sk&f 110679 | |||
ulimorelin | ulimorelin: ghrelin agonist; an 18-membered macrocycle containing 3 amide bonds and a secondary amine as well as 4 stereogenic centers; belongs to macrocyclic peptidomimetics | oligopeptide | |
n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine | N-(3-fluorophenyl)-1-((4-(((3S)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine: a small molecule motilin receptor agonist; structure in first source | acetamides | |
yil 781 | YIL 781: an appetite suppressant and weight loss promoter; structure in first source | ||
nitd 609 | NITD 609: an antimalarial and coccidiostat; structure in first source | ||
gsk 2334470 | GSK 2334470: a PDK1 inhibitor; structure in first source | indazoles |